1. Cheson BD, Pfistner B, Juweid ME, et al. International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579-586.
2. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571-578.
3. Rigacci L, Vitolo U, Nassi L, et al. Positron emission tomography in the staging of patients with Hodgkin’s lymphoma. A prospective multicentric study by the Intergruppo Italiano Linfomi. Ann Hematol 2007; 86: 897-903.
4. Sato K, Ozaki K, Fujiwara S, et al. Incidental carcinomas detected by PET/CT scans in patients with malignant lymphoma. Int J Hematol 2010; 92: 647-650.
5. Diepstra A, van der Graaf AM, Vos HJTWM, et al. Serum TARC levels correspond with tumor load and response to chemotherapy in classical Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3663.
6. Viviani S, Mazzocchi A, Bonfante V, et al. TARC is useful as additional prognostic factor for Hodgkin’s lymphoma outcome. Blood (ASH Annual Meeting Abstracts) 2009; 114: 1557.
7. Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica 2006; 91: 482-489.
8. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 2007; 25: 3746-3752.
9. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkinęs disease. International Prognostic Factors Project on Advanced Hodgkinęs Disease. N Engl J Med 1998;339: 1506-1514.
10. Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol 2009; 27: 1906-1914.
11. Avigdor A, Bulvik S, Levi I, et al. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin’s lymphoma. Ann Oncol 2010; 21: 126-132.
12. Dann EJ, Bar-Shalom R, Tamir A, et al. A functional dynamic scoring model to elucidate the significance of post-induction interim fluorine-18-fluorodeoxyglucose positron emission tomography findings in patients with Hodgkin’s lymphoma. Haematologica 2010; 95: 1198-1206.
13. Markova J, Kobe C, Skopalova M, et al. FDG-PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced stage Hodgkin’s lymphoma has a high negative predictive value. Ann Oncol 2009; 20: 1270-1274.
14. Gallamini A, Bonfante V, Levis A, et al. Early interim FDG-PET during intensified BEACOPP therapy shows a lower predictive value than during conventional ABVD chemotherapy. Haematologica 2007; 92(Suppl 2): 144.
15. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma 2009; 50: 1257-1260.
16. Radford JA, O’Doherty MJ, Barrington S, et al. Results of the 3rd planned interim analysis of the UK NCRI RAPID Trial (Involved field radiotherapy versus no further treatment) in patients with clinical stages IA/IIA Hodgkin lymphoma and a “negative“ 18FDG-PET scan after 3 cycles ABVD. Haematologica 2010; 95(suppl. 4): 32.
17. Yeddes I, Meignan M, Bardet S, et al. Positive interim PET after 2 ABVD is more frequent in patients with unfavourable stage I/II Hodgkin lymphoma and bulky mediastinum than in non-bulky. The EORTC-GELa-IIL H10 trial experience. Haematologica 2010; 95 (suppl. 4): 49.
18. Dann EJ, Bar-Shalom R, Tamir A, et al. Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood 2007; 109: 905-909.
19. Terasawa T, Nihashi T, Hotta T, Nagai H. 18F-FDG PET for posttherapy assessment of Hodgkin’s disease and aggressive Non-Hodgkin’s lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.
20. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-3994.
21. Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease. Ann Oncol 2003; 14: 123-130.
22. Mocikova H, Obrtlikova P, Vackova B, et al. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010; 21: 1222-1227.
23. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009; 27: 1781-1787.
24. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin’s lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010; 21: 1053-1057.
25. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease, results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
26. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 2002; 359: 2065-2071.
27. Johnston PB, Inwards DJ, Colgan JP, et al. A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 2010; 85: 320-324.
28. Dickinson M, Ritchie D, DeAngelo DJ, et al. Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma. Br J Haematol 2009; 147: 97-101.
29. Brice P, Bastion Y, Diviné M, et al. Analysis of prognostic factors after the first relapse of Hodgkin’s disease in 187 patients. Cancer 1996; 78: 1293-1299.
30. Moskowitz CH, Nimer SD, Zelentz AD, et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001; 97: 616-623.
31. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 2002; 20: 221-230.
32. Terasawa T, Dahabreh IJ, Nihashi T. Fluorine-18-fluorodeoxyglucose positron emission tomography in response assessment before high-dose chemotherapy for lymphoma: a systematic review and meta-analysis. Oncologist 2010; 15: 750-759.
33. Mocikova H, Pytlik R, Markova J, et al. Positive pre-transplantation positron emission tomography indicates poor prognosis in relapsed Hodgkin lymphoma patients. Haematologica 2010; 95 (suppl. 4): 27.